基石藥業(02616.HK)獲授抗體偶聯藥物LCB71韓國以外之開發及商業權
基石藥業(02616.HK)公布,公司與LegoChem Biosciences訂立授權協議,據此LegoChem授予獨家許可以允許公司於韓國境外地區開發並商業化LCB71,一種以受體酪氨酸激(酉每)樣孤兒受體1(ROR1)為靶點的臨床前階段抗體偶聯藥物。
LegoChem有權就開發、監管及商業里程碑收取總額為1,000萬美元的預付款及總額為3.54億美元的或然付款。此外,LegoChem有權收取基於LCB71淨銷售額的分層特許權使用費。於簽立授權協議後,公司將負責承擔於韓國境外地區LCB71所有正在進行的以及未來試驗有關的開發和監管事務相關活動的所有費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.